Select display options below. (Cookies need to be enabled in your browser!)
Colors: High contrast    Default    Font Size: X-Large    Large    Medium    Default    Small   
 
 
Research & Clinical Trials

Study Detail: Genentech Anti-Factor D

Trial Description Summary : First human trials of new human monoclonal antibody given one time intra-vitrally for Geographic Atrophy (Dry macular degeneration)

Basic Trial Information
Phase: 1a 
Disease: Geographic Atrophy (dry macular degeneration)
Sponsor: Genentech
Protocol Number: CFD4711g
Status: Enrolling

Study Duration: 6 months plus 2 week screening period  

Eligibility Criteria
 Inclusion Criteria
     GA at least 0.75 disc areas in the absence of CNV
     BCVA 20/125-20/400 inclusive

  Exclusion Criteria
     Wet AMD in either eye
     Diabetic retinopathy
     Previous ITV drug delivery
     Use of Visudyne, external-beam radiation therapy or TTT in EITHER eye
     Any prior treatment (except vitamins/mineral) for wet or dry AMD in either eye
 
 The above inclusion/exclusion criteria is not complete and the study coordinator will do a complete screening.

Study Title : A phase 1a, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy

Trial Contact Information
Site: Beachwood 
Study Coordinator: Dianne H     216/831-5704 x 253